AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The most significantly enriched pathways included prostate cancer, MAPK signaling pathway, Ras signaling pathway, melanoma, PI3K-Akt signaling pathway, pancreatic cancer, chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, gastric cancer, and proteoglycans in cancer.